Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Multicenter Phase III Study of QLC5508 Versus Investigator's Choice Chemotherapy in Pretreated Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Conditions
Interventions
QLC5508
Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)
Locations
1
China
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Start Date
April 20, 2026
Primary Completion Date
June 5, 2028
Completion Date
July 5, 2029
Last Updated
April 24, 2026
NCT07359417
NCT05473156
NCT06709417
NCT06710665
NCT07016737
NCT06504615
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions